Pharmacological inhibition of thioredoxin reductase increases insulin secretion and diminishes beta cell viability.
Animals
Apoptosis
/ drug effects
Benzene Derivatives
/ pharmacology
Cell Line
Cell Survival
/ drug effects
Dose-Response Relationship, Drug
Female
Glucose
/ metabolism
Insulin Secretion
/ drug effects
Insulin-Secreting Cells
/ drug effects
Islets of Langerhans
/ drug effects
Mice
Organogold Compounds
/ pharmacology
Thioredoxin-Disulfide Reductase
/ antagonists & inhibitors
Time Factors
Cytosolic calcium concentration
Glucose
Insulin secretion
NADPH
Thioredoxin
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
10
12
2019
accepted:
22
12
2020
pubmed:
20
1
2021
medline:
15
12
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
Apparently, both a decrease in beta cell function and in beta cell mass contribute to the progressive worsening of type 2 diabetes. So, it is of particular interest to define factors which are relevant for the regulation of insulin secretion and at the same time for the maintenance of beta cell mass. The NADPH-thioredoxin system has a candidate role for such a dual function. Here, we have characterized the effects of a highly specific inhibitor of thioredoxin reductase, AM12, on the viability and function of insulin-secreting MIN6 cells and isolated NMRI mouse islets. Viability was checked by MTT testing and the fluorescent live-dead assay. Apoptosis was assessed by annexin V assay. Insulin secretion of perifused islets was measured by ELISA. The cytosolic Ca
Identifiants
pubmed: 33464387
doi: 10.1007/s00210-020-02046-2
pii: 10.1007/s00210-020-02046-2
pmc: PMC8208932
doi:
Substances chimiques
Benzene Derivatives
0
Organogold Compounds
0
thioredoxin reductase inhibitor AM12
0
Thioredoxin-Disulfide Reductase
EC 1.8.1.9
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1133-1142Références
Diabetes. 2020 Jul;69(7):1341-1354
pubmed: 32245800
J Immunol. 1996 Jun 1;156(11):4092-9
pubmed: 8666774
FEBS Lett. 2014 Apr 17;588(8):1278-87
pubmed: 24583073
Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8895-9
pubmed: 22848030
J Exp Med. 1998 Oct 19;188(8):1445-51
pubmed: 9782121
Diabetes. 2008 Apr;57(4):938-44
pubmed: 18171713
J Vet Med Sci. 2010 Mar;72(3):321-6
pubmed: 19996565
Arch Biochem Biophys. 2017 Mar 1;617:101-105
pubmed: 27665998
Diabetologia. 1992 May;35(5):482-5
pubmed: 1387858
Diabetes. 2005 Jul;54(7):2132-42
pubmed: 15983215
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Endocrinology. 1990 Jul;127(1):126-32
pubmed: 2163307
J Inorg Biochem. 2016 Jul;160:140-8
pubmed: 26850306
J Immunol Methods. 1994 Dec 28;177(1-2):101-11
pubmed: 7822816
Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E373-93
pubmed: 16849626
Antioxid Redox Signal. 2004 Apr;6(2):269-75
pubmed: 15025928
Free Radic Biol Med. 2014 Jan;66:75-87
pubmed: 23899494
Diabetes. 2000 Nov;49(11):1751-60
pubmed: 11078440
Semin Cancer Biol. 2006 Dec;16(6):452-65
pubmed: 17056271
J Exp Med. 1995 Nov 1;182(5):1545-56
pubmed: 7595224
J Biol Chem. 2006 Aug 4;281(31):21884-21891
pubmed: 16766796
Biochem J. 2000 Feb 15;346 Pt 1:1-8
pubmed: 10657232
J Clin Invest. 2015 Oct 1;125(10):3847-60
pubmed: 26389676
J Biol Chem. 2019 Mar 29;294(13):4843-4853
pubmed: 30659092
Sci Rep. 2019 Feb 27;9(1):2895
pubmed: 30814610
J Clin Invest. 2015 Oct 1;125(10):3754-6
pubmed: 26389672
Mol Endocrinol. 2009 Jun;23(6):893-900
pubmed: 19299446
Diabetologia. 2008 Jan;51(1):101-9
pubmed: 17960358
Arch Biochem Biophys. 1993 Jun;303(2):474-82
pubmed: 8390225
Biochem Biophys Res Commun. 2010 May 21;396(1):120-4
pubmed: 20494123